Caster Sememya is back in the news. You may remember the South African middle distance runner caused all sorts of controversy when she won gold in the 800 meters at the London Olympics in 2012, and then again in Rio in 2016. The issue is that Ms. Semenya is hyperandrogenic, i.e. she naturally has an unusual amount of male hormones like testosterone, a conditional sometimes also referred to as a difference of sexual development or DSD. This helps her to be faster and stronger than most women, giving her, according to some, an unfair advantage when competing against other female athletes.
In 2018, the International Association of Athletics Federations (IAAF) brought in a new policy for hyperandrogenism, which required such athletes to conform to much stricter testosterone levels, in order to "create a level playing field in female sport". This basically requires athletes like Ms. Semenya and India's Dutee Chand to take androgen suppression medication to bring them closer to female norms, which of course has a direct impact on their athletic performance.
After this ruling, Ms. Semenya took her case to tbe Court of Arbitration for Sport (CAS), arguing that the new IAAF policy discriminated against her. And the reason she is back in the news now is because - against the advice of both the World Medical Association and the Human Rights Special Procedures body of the United Nations - the CAS has just sided with the IAAF and ruled that the stricter hyperandrogenism policy should continue, at least for now, even though it admitted that the policy is in fact discriminatory, and that it could not be sure that it would be fairly applied.
She has 30 days in which to appeal the case to the Swiss Tribunal Courts. But as things stand, Ms. Semenya and Ms. Chand will either have to take the androgen suppression drugs in the run up to the Tokyo 2020 Olympics, or to miss the Games completely.
My take on all this? Jonas Valanciunas of the Toronto Raptors is not banned from playing in the NBA because he happens to be seven feet tall. 'Nuff said.
No comments:
Post a Comment